Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non–Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)-Reference-Cited by-同舟云学术

Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non–Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)

Published:2022-11 Issue:7 Volume:23 Page:e395-e399
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Liu Si-Yang Maggie^ORCID,Yan Hong-Hong,Wei Xue-Wu,Lu Chang,Dong Xiao-Rong,Du Yingying,Cui Jiu-Wei,Chen Yuan,Ma Rui,Wang Bu-Hai,Zhou Zhen,Cang Shun-Dong,Yang Jin-Ji,Tu Hai-Yan,Zhang Xu-Chao,Zhong Wen-Zhao,Zhou Qing,Wu Yi-Long^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

2. Osimertinib in Resected EGFR-mutated non-small-cell lung cancer;Wu;N Engl J Med,2020

3. Alectinib versus Crizotinib in Untreated ALK-positive non-small-cell lung cancer;Peters;N Engl J Med,2017

4. Phase II study of Crizotinib in east asian patients with ROS1-positive advanced non-small-cell lung cancer;Wu;J Clin Oncol,2018

5. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug development and evidence for lung cancer targeted therapy in Eastern Asia;The Lancet Regional Health - Western Pacific;2024-08

2. Clinical data mining: challenges, opportunities, and recommendations for translational applications;Journal of Translational Medicine;2024-02-20

3. Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention;Medicine Advances;2023-12

4. Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial;eClinicalMedicine;2023-10

5. First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial;Nature Medicine;2023-07-24